Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›
Research›
Government Agencies›
California Institute for Regenerative Medicine›
Website
AddedFeb 13, 2024
UpdatedJun 28, 2026
California Institute for Regenerative Medicine

California Institute for Regenerative Medicine

Operating

CIRM: A California-based research institute, established in 2004, specializing in stem cell research.

Founded
2005
Location
San Francisco, CA, US
Loading
Overview
Compare
Employees
Website

Website

An index of every page on cirm.ca.gov, by section.

15 pages across 5 sections · Updated Jul 21, 2026·

Homepage

California Institute for Regenerative Medicine's front door: current positioning and top-line messaging.

cirm.ca.gov

ContactContact Us

Sales, support, and partnership channels for reaching California Institute for Regenerative Medicine directly.

cirm.ca.gov/contact-us

ComparisonImc F106c Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma Prism Mel 301

6 comparison pages published by California Institute for Regenerative Medicine.

  • Imc F106c Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma Prism Mel 301
  • Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared with Pembrolizumab Alone in Participants with Untreated Advanced Melanoma
  • Suprame Actengine Ima203 vs Investigators Choice of Treatment in Previously Treated Unresectable or Metastatic Cutaneous Melanoma
  • Comparison of the Human Acellular Vessel Hav with Fistulas as Conduits for Hemodialysis
  • A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate 2 or High Risk Myelofibrosis Mf Who Have Not Responded to Janus Kinase Jak Inhibitor Treatment
  • Iltamiocel Compared to Placebo for Chronic Fecal Incontinence in Females with Obstetric Injury

Blog08302011 Hope vs Hype Stem Cell Research

Product updates, deep-dives, and company thinking: California Institute for Regenerative Medicine's 6-post archive.

  • 08302011 Hope vs Hype Stem Cell Research
  • 08262011 Progress Toward Stem Cell Clinical Trials
  • 08252011 Guest Blogger Alan Trounson What Mouses Toe Tells Us About Cirms Investment
  • 08242011 Salamanders Mice and Men Digit Regeneration Mechanisms Revealed
  • 08222011 New Journal Focuses Developing Stem Cell Therapies
  • 08192011 Gmp Grade Embryonic Stem Cell Lines Approved Nih

PrivacyPrivacy Policy

How California Institute for Regenerative Medicine collects, uses, and safeguards data: the canonical policy set.

cirm.ca.gov/privacy-policy